Company research
ArriVent BioPharma, Inc.
CIK 1868279Updated Sep 25, 2026
SecurityAVBP · NASDAQ · equity
AVBP price & chart
Loading TradingView…
NASDAQ:AVBP on TradingView ↗About the company
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
In the news
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting ↗
Recent filings
10-Q filing
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition
Items 1.01, 2.02, 9.01
4 filing
4 filing
4 filing
Show 5 more recent filings
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01, 9.01
424B5 filing
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 333,169,000Source | 274,942,000Source | 163,098,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 45,540,000Source | 74,293,000Source | 150,389,000Source |
| Assets, CurrentUSD | 332,897,000Source | 226,979,000Source | 159,968,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 20,076,000Source | 8,116,000Source | 9,579,000Source |
| Operating Lease, Right-of-Use AssetUSD | 13,000Source | 154,000Source | 291,000Source |
| Other Assets, NoncurrentUSD | 190,000Source | 126,000Source | 107,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 25,945,000Source | 17,288,000Source | 11,801,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | — |
| Additional Paid in CapitalUSD | 711,847,000Source | 496,195,000Source | 4,652,000Source |
| Retained Earnings (Accumulated Deficit)USD | -404,641,000Source | -238,333,000Source | -157,845,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 14,000Source | -211,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 307,224,000Source | 257,654,000Source | -153,193,000Source |
| Liabilities and EquityUSD | 333,169,000Source | 274,942,000Source | 163,098,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 25,945,000Source | 17,274,000Source | 11,624,000Source |
| Operating Lease, Liability, CurrentUSD | 14,000Source | 162,000Source | 140,000Source |
| Accounts Payable, CurrentUSD | 5,934,000Source | 3,782,000Source | 4,532,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 14,000Source | 177,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 19,997,000Source | 13,330,000Source | 6,952,000Source |
| Short-term InvestmentsUSD | 267,281,000Source | 144,570,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,520,000Source | 3,208,000Source | 895,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -160,588,000Source | -70,212,000Source | -55,842,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -71,228,000Source | -192,465,000Source | — |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 203,063,000Source | 186,581,000Source | 42,859,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -28,753,000Source | -76,096,000Source | -12,983,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 45,540,000Source | 74,293,000Source | 150,389,000Source |
| Supplemental disclosure of cash flow information: | |||
| Income Taxes Paid, NetUSD | 0Source | — | — |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 12,520,000Source | 3,208,000Source | 895,000Source |
| Depreciation, Amortization and Accretion, NetUSD | -3,026,000Source | — | — |
| General and Administrative ExpenseUSD | 24,183,000Source | 15,304,000Source | 9,706,000Source |
| Net Income (Loss) Attributable to ParentUSD | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Operating ExpensesUSD | 177,534,000Source | 94,308,000Source | 74,590,000Source |
| Operating Lease, ExpenseUSD | 200,000Source | 200,000Source | 200,000Source |
| Payments to Acquire InvestmentsUSD | 272,934,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | 202,631,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 502,000Source | 631,000Source | 354,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -177,534,000Source | -94,308,000Source | -74,590,000Source |
| Net Income (Loss) Attributable to ParentUSD | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Earnings Per Share, BasicUSD per share | -4.32Source | -2.56Source | -32.38Source |
| Earnings Per Share, DilutedUSD per share | -4.32Source | -2.56Source | -32.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 38,462,600Source | 31,469,328Source | 2,140,951Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 38,462,600Source | 31,469,328Source | 2,140,951Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 24,183,000Source | 15,304,000Source | 9,706,000Source |
| Investment Income, NetUSD | 11,226,000Source | 13,820,000Source | 5,257,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Operating ExpensesUSD | 177,534,000Source | 94,308,000Source | 74,590,000Source |
| Operating Lease, ExpenseUSD | 200,000Source | 200,000Source | 200,000Source |
| Research and Development ExpenseUSD | 153,351,000Source | 79,004,000Source | 64,884,000Source |
Filing attachments
tm2622880d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622880d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2026 Financial Results Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial c…
Read attachment ↗avbp-20260511xex99d1.htm · 8-K · 2026-05-11
EX-99.1 2 avbp-20260511xex99d1.htm EX-99.1 Exhibit 99.1 ArriVent BioPharma Reports First Quarter 2026 Financial Results Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the clinic and plans to dose its first patient in 2H 2026, initially for ovarian and endometrial cancers ARR-002’s superior anti-tumor activity and …
Read attachment ↗avbp-20260317xex99d1.htm · 8-K · 2026-03-17
EX-99.1 2 avbp-20260317xex99d1.htm EX-99.1 Exhibit 99.1 ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models Superior anti-tumor activity of ARR-002 in ovarian cancer models compared to sing…
Read attachment ↗